Analisis Aktivitas Quercetin Moringa oleifera terhadap Inhibisi Acetylcholinesterase (AChE) pada Terapi Alzheimer dengan Pendekatan In Silico

JULIA ANGELINA SAFITRI; TAMAM JAUHAR; PETER GUNAWAN TANDEAN; ERIC MAYO DAGRADI

doi:10.30649/htmj.v22i2.762

Authors

JULIA ANGELINA SAFITRI Faculty of Medicine, Hang Tuah University, Surabaya
TAMAM JAUHAR Faculty of Medicine, Hang Tuah University, Surabaya
PETER GUNAWAN TANDEAN Faculty of Medicine, Hang Tuah University, Surabaya
ERIC MAYO DAGRADI Faculty of Medicine, Hang Tuah University, Surabaya

DOI:

https://doi.org/10.30649/htmj.v22i2.762

Keywords:

Keywords : Alzheimer’s disease, In silico, Acetylcholinesterase (AChE), Moringa oleifera, Quercetin.

Abstract

Many plants contain active compounds that can be used to treat various diseases. One of these plants is Moringa oleifera Lam. (drumstick tree), which is known for its benefits in treating Alzheimer’s disease. The active compound quercetin found in Moringa oleifera has the ability to inhibit acetylcholinesterase (AChE), one of the primary causes of Alzheimer’s disease. Quercetin also has similar potential and functions to donepezil, a drug commonly used in Alzheimer’s therapy. This study aimed to examine the role of quercetin in inhibiting AChE as part of Alzheimer’s therapy using an in silico approach. The research utilized molecular docking, pharmacokinetic ADME predictions, and toxicity predictions to evaluate the active compound quercetin. The results showed that quercetin has similar potential to donepezil in inhibiting AChE, as they both share the same binding sites. Pharmacokinetic predictions revealed that quercetin is well-absorbed in the intestine and has better skin permeability compared to donepezil, although its ability to cross the Blood-Brain Barrier (BBB) is limited. Quercetin has a limited distribution in the body, a high binding affinity to plasma proteins, and acts as an inhibitor of CYP1A2 and CYP2C9 enzymes. Additionally, quercetin is effectively excreted by the body. It is predicted to have potential as an oral medication and is categorized as a class III compound based on its LD50 toxicity value

Keywords : Alzheimer’s disease, In silico, Acetylcholinesterase (AChE), Moringa oleifera, Quercetin

References

Alzheimer’s Association. (2020). 2020 Alzheimer’s disease facts and figures. Alzheimer’s and Dementia, 16(3), 391–460. doi: 10.1002/alz.12068

Alzheimer’s Association. (2023). 2023 Alzheimer’s disease facts and figures. Alzheimer’s and Dementia, 19(4), 1598–1695. doi: 10.1002/alz.13016

Benfenati, E. (2016). In Silico Methods for Predicting Drug Toxicity. Retrieved from http://www.springer.com/series/7651

Brust, J. C. M. (John C. M. ). (2019). Current diagnosis & treatment. Neurology.

Chen, X., Li, H., Tian, L., Li, Q., Luo, J., & Zhang, Y. (2020). Analysis of the Physicochemical Properties of Acaricides Based on Lipinski’s Rule of Five. Journal of Computational Biology, 27(9), 1397–1406. doi: 10.1089/cmb.2019.0323

Islam, M. S., Quispe, C., Hossain, R., Islam, M. T., Al-Harrasi, A., Al-Rawahi, A., Martorell, M., Mamurova, A., Seilkhan, A., Altybaeva, N., Abdullayeva, B., Docea, A. O., Calina, D., & Sharifi-Rad, J. (2021). Neuropharmacological Effects of Quercetin: A Literature-Based Review. In Frontiers in Pharmacology (Vol. 12). Frontiers Media S.A. doi: 10.3389/fphar.2021.665031

Khan, H., Ullah, H., Aschner, M., Cheang, W. S., & Akkol, E. K. (2020). Neuroprotective effects of quercetin in alzheimer’s disease. In Biomolecules (Vol. 10, Issue 1). MDPI AG. doi: 10.3390/biom10010059

Kim, H. S., Jeong, C.-H., & Lee, J.-K. (2022). Neuroprotective effects of Moringa oleifera leaf extracts. Food and Life, 2022(1), 19–26. doi: 10.5851/fl.2022.e1

Mahaman, Y. A. R., Huang, F., Wu, M., Wang, Y., Wei, Z., Bao, J., Salissou, M. T. M., Ke, D., Wang, Q., Liu, R., Wang, J. Z., Zhang, B., Chen, D., & Wang, X. (2018). Moringa Oleifera Alleviates Homocysteine-Induced Alzheimer’s Disease-Like Pathology and Cognitive Impairments. Journal of Alzheimer’s Disease, 63(3), 1141–1159. doi: 10.3233/JAD-180091

Marucci, G., Buccioni, M., Ben, D. D., Lambertucci, C., Volpini, R., & Amenta, F. (2021). Efficacy of acetylcholinesterase inhibitors in Alzheimer’s disease. In Neuropharmacology (Vol. 190). Elsevier Ltd. doi: 10.1016/j.neuropharm.2020.108352

Pires, D. E. V, Blundell, T. L., & Ascher, D. B. (2015). pkCSM: predicting small-molecule pharmacokinetic properties using graph-based signatures.

Pirie, R., Stanway-Gordon, H. A., Stewart, H. L., Wilson, K. L., Patton, S., Tyerman, J., Cole, D. J., Fowler, K., & Waring, M. J. (2024). An analysis of the physicochemical properties of oral drugs from 2000 to 2022. RSC Medicinal Chemistry. doi: 10.1039/d4md00160e

Qi, P., Li, J., Gao, S., Yuan, Y., Sun, Y., Liu, N., Li, Y., Wang, G., Chen, L., & Shi, J. (2020). Network Pharmacology-Based and Experimental Identification of the Effects of Quercetin on Alzheimer’s Disease. Frontiers in Aging Neuroscience, 12. doi: 10.3389/fnagi.2020.589588

Talevi, A. (2022). The ADME Encyclopedia (A. Talevi, Ed.). Cham: Springer International Publishing. doi: 10.1007/978-3-030-84860-6

Tang, S., Chen, R., Lin, M., Lin, Q., Zhu, Y., Ding, J., Hu, H., Ling, M., & Wu, J. (2022). Accelerating AutoDock Vina with GPUs. Molecules, 27(9). doi: 10.3390/molecules27093041

Trang A, & Khandar PB. (2023). Physiology, Acetylcholinesterase. StatPearls [Internet].

Zang, Q., Mansouri, K., Williams, A. J., Judson, R. S., Allen, D. G., Casey, W. M., & Kleinstreuer, N. C. (2017). In Silico Prediction of Physicochemical Properties of Environmental Chemicals Using Molecular Fingerprints and Machine Learning. Journal of Chemical Information and Modeling, 57(1), 36–49. doi: 10.1021/acs.jcim.6b00625

Zwickl, C. M., Graham, J. C., Jolly, R. A., Bassan, A., Ahlberg, E., Anger, L. T., Beilke, L., Bellion, P., Brigo, A., Burleigh-Flayer, H., Cronin, M. T., Devlin, A. A., Fish, T., Glowienke, S., Gromek, K., Karmaus, A., Kemper, R., Kulkarni, S., Lo Piparo, E., … jj, M. (2022). Principles and Procedures for Assessment of Acute Toxicity Incorporating In Silico Methods 2 3. Retrieved from https://www.elsevier.com/open-access/userlicense/1.0/